IMGN Stock Overview
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ImmunoGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.23 |
| 52 Week High | US$31.25 |
| 52 Week Low | US$3.61 |
| Beta | 1.17 |
| 11 Month Change | 4.94% |
| 3 Month Change | 98.16% |
| 1 Year Change | 617.93% |
| 33 Year Change | 196.58% |
| 5 Year Change | 452.74% |
| Change since IPO | 228.74% |
Recent News & Updates
Recent updates
Final Countdown: AbbVie's Imminent Closure With ImmunoGen And What It Means
Feb 09ImmunoGen, Inc.'s (NASDAQ:IMGN) Intrinsic Value Is Potentially 40% Above Its Share Price
Jan 09
There's Reason For Concern Over ImmunoGen, Inc.'s (NASDAQ:IMGN) Massive 95% Price Jump
Dec 22ImmunoGen (NASDAQ:IMGN) Is Using Debt Safely
Oct 20Analysts Just Made A Massive Upgrade To Their ImmunoGen, Inc. (NASDAQ:IMGN) Forecasts
Aug 06Is ImmunoGen, Inc. (NASDAQ:IMGN) Trading At A 48% Discount?
Jul 20Forecast: Analysts Think ImmunoGen, Inc.'s (NASDAQ:IMGN) Business Prospects Have Improved Drastically
May 03ImmunoGen, Inc.'s (NASDAQ:IMGN) Low P/S No Reason For Excitement
Apr 18Is ImmunoGen (NASDAQ:IMGN) In A Good Position To Deliver On Growth Plans?
Feb 25What Does The Future Hold For ImmunoGen, Inc. (NASDAQ:IMGN)? These Analysts Have Been Cutting Their Estimates
Jan 03Shareholder Returns
| IMGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.6% | 1.2% | 1.0% |
| 1Y | 617.9% | 21.2% | 33.7% |
Return vs Industry: IMGN exceeded the US Biotechs industry which returned 4% over the past year.
Return vs Market: IMGN exceeded the US Market which returned 20.6% over the past year.
Price Volatility
| IMGN volatility | |
|---|---|
| IMGN Average Weekly Movement | 24.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IMGN's share price has been volatile over the past 3 months.
Volatility Over Time: IMGN's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 277 | Mark Enyedy | www.immunogen.com |
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate.
ImmunoGen, Inc. Fundamentals Summary
| IMGN fundamental statistics | |
|---|---|
| Market cap | US$8.36b |
| Earnings (TTM) | -US$73.52m |
| Revenue (TTM) | US$287.61m |
29.1x
P/S Ratio-113.7x
P/E RatioIs IMGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMGN income statement (TTM) | |
|---|---|
| Revenue | US$287.61m |
| Cost of Revenue | US$211.62m |
| Gross Profit | US$76.00m |
| Other Expenses | US$149.52m |
| Earnings | -US$73.52m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 26.42% |
| Net Profit Margin | -25.56% |
| Debt/Equity Ratio | 12.8% |
How did IMGN perform over the long term?
See historical performance and comparison